<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2881">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04358406</url>
  </required_header>
  <id_info>
    <org_study_id>BTI-202</org_study_id>
    <nct_id>NCT04358406</nct_id>
  </id_info>
  <brief_title>Rhu-pGSN for Severe Covid-19 Pneumonia</brief_title>
  <official_title>A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof-Of-Concept Study To Evaluate Efficacy And Safety Of Recombinant Human Plasma Gelsolin (Rhu-pGSN) Added To Standard Of Care In Subjects With Severe Covid-19 Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioAegis Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioAegis Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Objectives:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To assess the efficacy (survival without organ failure on Day 14) of three doses of&#xD;
           rhu-pGSN administered intravenously (IV) plus standard of care (SOC) to hospitalized&#xD;
           subjects with a primary diagnosis of COVID-19 pneumonia and a severity score of 4, 5 or&#xD;
           6 on the World Health Organization (WHO) 9-point severity scale&#xD;
&#xD;
        -  To evaluate the safety and tolerability of three IV doses of rhu-pGSN administered to&#xD;
           hospitalized subjects with a primary diagnosis of COVID-19 pneumonia and a severity&#xD;
           score of 4, 5, or 6 on the WHO 9-point severity scale&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To further assess the efficacy of IV administered rhu-pGSN&#xD;
&#xD;
        -  To assess changes in WHO 9-point severity score for SOC with or without rhu-pGSN&#xD;
&#xD;
        -  To evaluate the effect of administered rhu-pGSN on survival rates&#xD;
&#xD;
        -  To assess the relationship of pGSN levels (and other biomarkers) at baseline with&#xD;
           clinical outcomes&#xD;
&#xD;
        -  [OPTIONAL] To follow the pharmacokinetics (PK) of administered rhu-pGSN&#xD;
&#xD;
      Immunogenicity&#xD;
&#xD;
      • To investigate the development of antibodies against rhu-pGSN post-treatment&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Efficacy and safety of IV rhu-pGSN on top of SOC will be evaluated initially in 60&#xD;
      participants representative of the drug target population: high-risk subjects with acute&#xD;
      severe pneumonia due to COVID-19. The rhu-pGSN dose will be based on actual body weight given&#xD;
      at 12 mg/kg. Three doses will be given at 0, 12 and 24 hours intervals promptly after&#xD;
      enrollment by IV infusion through a 0.2 µm filter. Participants will be randomized 1:1&#xD;
      rhu-pGSN or placebo. Interim safety analyses will be conducted after enrollment of 12, 24,&#xD;
      36, and 48 patients.&#xD;
&#xD;
      The primary efficacy outcome will be the proportion of patients surviving on Day 14 without&#xD;
      mechanical ventilation, vasopressors or dialysis. Secondary efficacy outcomes will include:&#xD;
      daily change in 9-point WHO severity score through at least Day 14; all-cause mortality at&#xD;
      Days 28 and 90; time to death (Kaplan-Meier survival analysis); proportion of subjects alive&#xD;
      on Days 7, 28, 60, and 90 without: ongoing use of vasopressors, ongoing intubation/mechanical&#xD;
      ventilation, ongoing residence in an intensive care unit (ICU), new ongoing need for&#xD;
      dialysis/renal replacement therapy; proportion of subjects discharged to home or immediate&#xD;
      prior residence by Day 28; days on the ventilator; length of stay in hospital and in ICU and&#xD;
      re-admission to an acute-care hospital up to Day 90. Safety of administration of rhu-pGSN at&#xD;
      the indicated dosage will also be evaluated.&#xD;
&#xD;
      Baseline and sequential levels of pGSN and inflammatory biomarkers will be measured. On days&#xD;
      1, 28, and 90, immunogenicity due to the formation of anti-pGSN antibodies will be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 30, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Randomized, blinded, placebo controlled interventional</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Treatment blinded to all but unblinded pharmacist</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Proportion of subjects alive not on vasopressors, mechanical ventilator, and dialysis</measure>
    <time_frame>Day 14</time_frame>
    <description>Proportion of subjects alive not on vasopressors, mechanical ventilator, and dialysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability: Proportion of subjects with serious adverse events (SAEs)</measure>
    <time_frame>Continuous through Day 28</time_frame>
    <description>Proportion of subjects with SAEs as judged by the investigator</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Daily change in the WHO 9-point severity score</measure>
    <time_frame>Daily through at least Day 14</time_frame>
    <description>Daily change in the 9-point Severity Score (ordinal scale) proposed by a special WHO committee for COVID-19 pneumonia where a score of 8 indicates death and 0 is no clinical or virological evidence of COVID-19 infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: All cause mortality rate at Days 28 and 90</measure>
    <time_frame>At Days 28 and 90</time_frame>
    <description>All cause mortality rate using Kaplan-Meier survival analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Proportion of subjects alive without the ongoing use of vasopressors, ongoing intubation/mechanical ventilation, ongoing residence in an intensive care unit (ICU), new ongoing need for dialysis/renal replacement therapy</measure>
    <time_frame>Days 7, 28, 60, and 90</time_frame>
    <description>Proportion of subjects alive without the ongoing use of vasopressors, ongoing intubation/mechanical ventilation, ongoing residence in an intensive care unit, new ongoing need for dialysis/renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Proportion of subjects discharged to home or immediate prior residence</measure>
    <time_frame>Continuous through Day 28</time_frame>
    <description>Proportion of subjects discharged to home or immediate prior residence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Length of stay (LOS) of surviving subjects in the hospital and in ICU</measure>
    <time_frame>Continuous through day 28</time_frame>
    <description>LOS of surviving subjects in the hospital and in ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Proportion of subjects readmitted to the hospital</measure>
    <time_frame>Up to 90 days</time_frame>
    <description>Proportion of subjects readmitted to the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability: Proportion of subjects with adverse events (AEs)</measure>
    <time_frame>Continuous through Day 28</time_frame>
    <description>Proportion of subjects with adverse events (AEs) graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability: Proportion of subjects with new or worsening clinically significant laboratory abnormalities</measure>
    <time_frame>Continuous through Day 28</time_frame>
    <description>Proportion of subjects with new or worsening clinically significant laboratory abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: Proportion of subjects with rhu-pGSN antibodies</measure>
    <time_frame>Days 1, 28, and 90</time_frame>
    <description>Proportion of subjects with rhu-pGSN antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum concentration (C max) of added rhu-pGSN</measure>
    <time_frame>Continuous through day 3</time_frame>
    <description>Blood samples for dose #1 will be collected within 15 minutes predose, and at 1 (±15 min), 2 (±15 min), 6 (±30 min), and 12 (±30 min) hours after end of administration (but prior to Dose #2); for Dose #3 within 15 minutes predose, and at 1 (±15 min), 2 (±15 min), 6 (±30 min), 12 (±30 min) and 24 (±30 min) hours after the end of administration (participants refusing these blood samplings can enter and remain in the trial).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Time to maximum concentration (T max) of added rhu-pGSN</measure>
    <time_frame>Continuous through day 3</time_frame>
    <description>Blood samples for dose #1 will be collected within 15 minutes predose, and at 1 (±15 min), 2 (±15 min), 6 (±30 min), and 12 (±30 min) hours after end of administration (but prior to Dose #2); for Dose #3 within 15 minutes predose, and at 1 (±15 min), 2 (±15 min), 6 (±30 min), 12 (±30 min) and 24 (±30 min) hours after the end of administration (participants refusing these blood samplings can enter and remain in the trial).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Half-life (T 1/2) of added rhu-pGSN</measure>
    <time_frame>Continuous through day 3</time_frame>
    <description>Blood samples for dose #1 will be collected within 15 minutes predose, and at 1 (±15 min), 2 (±15 min), 6 (±30 min), and 12 (±30 min) hours after end of administration (but prior to Dose #2); for Dose #3 within 15 minutes predose, and at 1 (±15 min), 2 (±15 min), 6 (±30 min), 12 (±30 min) and 24 (±30 min) hours after the end of administration (participants refusing these blood samplings can enter and remain in the trial)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the curve from time 0 to 8 hours (AUC 0-8) of added rhu-pGSN</measure>
    <time_frame>Continuous through day 3</time_frame>
    <description>Blood samples for dose #1 will be collected within 15 minutes predose, and at 1 (±15 min), 2 (±15 min), 6 (±30 min), and 12 (±30 min) hours after end of administration (but prior to Dose #2); for Dose #3 within 15 minutes predose, and at 1 (±15 min), 2 (±15 min), 6 (±30 min), 12 (±30 min) and 24 (±30 min) hours after the end of administration (participants refusing these blood samplings can enter and remain in the trial)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the curve from time 0 to infinity (AUC 0-inf) of added rhu-pGSN</measure>
    <time_frame>Continuous through day 3</time_frame>
    <description>Blood samples for dose #1 will be collected within 15 minutes predose, and at 1 (±15 min), 2 (±15 min), 6 (±30 min), and 12 (±30 min) hours after end of administration (but prior to Dose #2); for Dose #3 within 15 minutes predose, and at 1 (±15 min), 2 (±15 min), 6 (±30 min), 12 (±30 min) and 24 (±30 min) hours after the end of administration (participants refusing these blood samplings can enter and remain in the trial)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Sars-CoV2</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline in matched volume to treatment arm. Undistinguishable in syringe.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rhu-pGSN</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Recombinant human plasma gelsolin reconstituted for slow bolus injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human plasma gelsolin (Rhu-pGSN)</intervention_name>
    <description>Intravenous administration of rhu-pGSN at 12 mg/kg, 3 doses</description>
    <arm_group_label>Rhu-pGSN</arm_group_label>
    <other_name>gelsolin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline in matched volume to treatment arm. Undistinguishable in syringe.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hospitalized with laboratory-confirmed (RT-PCR+) or highly suspected (compatible with&#xD;
             at least bilobar lung involvement without another plausible diagnosis) COVID-19&#xD;
&#xD;
          -  Weight ≤100 kg&#xD;
&#xD;
          -  Within 24 hours of reaching a WHO severity score of 4-6 either:&#xD;
&#xD;
               -  At admission&#xD;
&#xD;
               -  While already hospitalized&#xD;
&#xD;
          -  Informed consent obtained from subject/next of kin/legal proxy&#xD;
&#xD;
          -  Primary admitting diagnosis of pneumonia supported by a compatible clinical&#xD;
             presentation with a documented infiltrate consistent with pneumonia on chest&#xD;
             radiograph or CT as assessed by the admitting emergency-department (ED), clinic, or&#xD;
             ward physician or equivalent caregiver&#xD;
&#xD;
          -  Recommended (not mandatory) guidance/discretionary criteria defining patients with&#xD;
             pneumonia satisfying all 4 categories below:&#xD;
&#xD;
               -  At least 2 symptoms: difficulty breathing, cough, production of purulent sputum,&#xD;
                  or chest pain&#xD;
&#xD;
               -  At least 2 vital sign abnormalities: fever, tachycardia, or tachypnea (thresholds&#xD;
                  -- fever: oral or core temperature &gt;100.4 °F [38 °C]; heart rate &gt;100 beats/min;&#xD;
                  respiratory rate &gt;24/min)&#xD;
&#xD;
               -  At least one finding of other clinical signs and laboratory abnormalities:&#xD;
                  hypoxemia (O2 saturation &lt;90%), clinical evidence of pulmonary consolidation, or&#xD;
                  leukocytosis or leukopenia&#xD;
&#xD;
               -  Chest imaging or CT showing new (or presumed new or worsening) pulmonary&#xD;
                  infiltrates&#xD;
&#xD;
                    -  Principal investigator to note radiologic findings in the electronic case&#xD;
                       report form (eCRF)&#xD;
&#xD;
                    -  Radiology report to be placed in the eCRF&#xD;
&#xD;
                    -  A copy of the radiograph attached to be saved for review&#xD;
&#xD;
          -  A hyperinflammatory status (defined by increased ferritin ≥500 µg/L, D-dimer ≥1000&#xD;
             ng/mL, or C-reactive protein (CRP) ≥75 mg/L)&#xD;
&#xD;
          -  During the course of the study starting at screening and for at least 6 months after&#xD;
             their final study treatment:&#xD;
&#xD;
               -  Female subjects of childbearing potential must agree to use 2 medically accepted&#xD;
                  birth control methods&#xD;
&#xD;
               -  Male subjects with a partner who might become pregnant must agree to use reliable&#xD;
                  forms of contraception (i.e., vasectomy, abstinence), or an acceptable method of&#xD;
                  birth control must be used by the partner&#xD;
&#xD;
               -  All subjects must agree not to donate sperm or eggs (ovocytes)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A negative RT-PCR test for COVID-19 during the evaluation of the present illness&#xD;
&#xD;
          -  Extracorporeal membrane oxygenation (ECMO)&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Active underlying cancer treated with systemic chemotherapy or radiation therapy&#xD;
             during the last 30 days&#xD;
&#xD;
          -  Transplantation of hematopoietic or solid organs&#xD;
&#xD;
          -  Chronic mechanical ventilation or dialysis&#xD;
&#xD;
          -  Otherwise unsuitable for study participation because of chronic, severe, end-stage,&#xD;
             and life-limiting underlying disease unrelated to COVID-19 likely to interfere with&#xD;
             management and assessment of acute pneumonia, only comfort or limited (non-aggressive)&#xD;
             care is to be given, or life expectancy &lt;6 months unrelated to acute COVID infection&#xD;
             in the opinion of the Investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark J DiNubile, MD</last_name>
    <role>Study Director</role>
    <affiliation>BioAegis Therapeutics Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark J DiNubile, MD</last_name>
    <phone>609-706-5866</phone>
    <email>mdinubile@bioaegistx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan L Levinson, PhD</last_name>
    <phone>19735394552</phone>
    <email>slevinson@bioaegistx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Spitalul Clinic de Boli Infecţioase şi Pneumoftiziologie</name>
      <address>
        <city>Timişoara</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Voichita Lazureanu, MD</last_name>
      <email>vlazureanu@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Elena Voichita Lazureanu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristian Iulian Oancea, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tamara Mirela Porosnicu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ovidiu Fira Mladinescu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Monica Marc, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Talida Georgiana Cut, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrada Roxana Garjoaba, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adelina Raluca Marinescu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sant Joan de Reus SAM University Hospital</name>
      <address>
        <city>Reus</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoni Castro Salomó, MD</last_name>
      <email>antoni.castro@urv.cat</email>
    </contact>
    <contact_backup>
      <last_name>Sandra Parra Perez, MD</last_name>
      <email>sandra.parra@urv.cat</email>
    </contact_backup>
    <investigator>
      <last_name>Antoni Castro Salomó, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandra Parra Perez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alba Àvila Juanpere, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pedro Pardo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Josep Colom, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mireia Feliu Masgoret, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simona Iftimie, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesc Marimon Cortes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Imma Vallverdú, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Salvador Hernández, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Texido Bruguera, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alba Catalá, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Benavent, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Natàlia Andreychuk Pasichna, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Tarragona Joan XXIII</name>
      <address>
        <city>Tarragona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Auget Quintillá, MD</last_name>
      <email>tauguet.hj23.ics@gencat.cat</email>
    </contact>
    <investigator>
      <last_name>Teresa Auget Quintillá, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jesús Miguel López Dupla, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Riesco, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Antonio Porras, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ajla Alibalic, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sonia Roig, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Maria Febrer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mercè Sirisi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Romania</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 16, 2020</study_first_submitted>
  <study_first_submitted_qc>April 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>Severe</keyword>
  <keyword>Cytokine storm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

